Open access
Oct 2026
Open-label Phase 1 study to evaluate drug-drug interactions between ulonivirine and islatravir in adults without HIV
No clinically meaningful DDIs were observed between ulonivirine 200 mg and islatravir 2 mg, supporting continued development of this combination for HIV-1 treatment, and safety parameters were comparable among all three periods.
Jesse C. Nussbaum, Michelle M. Pham, R. Vargo et al.
· Antimicrobial Agents and Che... · 0 citations